Bionovo Inc.  

(Public, OTCMKTS:BNVIQ)   Watch this stock  
Apr 8 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/103,871.00
Mkt cap 18,075.00
P/E     -
Div/yield     -
EPS -0.34
Shares 80.33M
Beta 33.26
Inst. own 0%

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin -15219.23% -5169.43%
Operating margin -13498.08% -8916.98%
EBITD margin - -7816.23%
Return on average assets -204.78% -87.14%
Return on average equity -417.31% -155.64%
Employees 5 -
CDP Score - -


5858 Horton St Ste 400
EMERYVILLE, CA 94608-2046
United States - Map
+1-510-6012000 (Phone)
+1-510-6015050 (Fax)

Website links


Bionovo, Inc. is a drug discovery and development company, which focuses on women's health and development of drugs for the treatment of cancer. The Company's drug candidates include Menerba, Seala, Bezielle, BN107 and BN108. Its Menerba is a selective estrogen receptor beta agonist, which reduces the frequency and severity of menopausal hot flashes. The Company has completed a randomized, double-blind, placebo-controlled Phase II clinical trial of Menerba. Bezielle is an orally delivered anti-cancer agent. The Company is engaged in an open label, multi-center Phase I/II trial of Bezielle for the treatment of advanced metastatic breast cancer. The Company's Seala is a selective estrogen receptor beta agonist, which acts as an intra-vaginal suppository. The Company's anti-cancer agents include BN107 and BN108, which are used for the treatment of advanced breast cancer. BN107 and BN108 are in pre-clinical development stage.